Samsung Bioepis Releases Second Quarter 2026 US Biosimilar Market Report

Key Takeaways

• 92 US biosimilars approved, 67 already launched.
• Adalimumab biosimilar adoption reaches 60% with private‑label inclusion.
• Ustekinumab biosimilar ASP falls to $753, a 73% drop.
• Denosumab biosimilar discounts range 6‑79% vs Prolia, up to 86% vs Xgeva.
• FDA guidance eases biosimilarity evidence, reducing comparative efficacy study demand.

Pulse Analysis

The latest Samsung Bioepis Quarterly Biosimilar Market Report, released for Q2 2026, shows the U.S. biosimilar landscape maturing at a rapid pace. With 92 biosimilars cleared by the FDA across 20 distinct biologics and 67 already on the market, the sector now covers roughly three‑quarters of approved products. The report also highlights two recent FDA draft guidances—one from October 2025 that downplays routine comparative efficacy studies, and a March 2026 revision that permits greater use of foreign comparator data. Together, these regulatory shifts are lowering development barriers and accelerating entry timelines.

Pricing volatility remains a defining feature of the market. Ustekinumab biosimilars saw their average sales price plunge to $753, a 73 % quarter‑over‑quarter decline driven by a methodological change that isolates the Medicare Part B loading dose. Denosumab biosimilars now trade at 6‑79 % discounts versus the reference Prolia and up to 86 % versus Xgeva, while eculizumab copies Bkemv and Epumsum are priced 9 % and 32 % below the originator. Such discount breadth pressures payers to reassess formulary placement and creates room for aggressive market‑share battles.

For manufacturers, the confluence of regulatory easing and aggressive pricing creates both opportunity and risk. Companies that can leverage analytical comparability and pharmacokinetic data to meet the new FDA expectations may shorten development cycles and capture early adopters, as illustrated by the 60 % adoption rate of adalimumab biosimilars after private‑label inclusion. However, steep price erosion—particularly for high‑cost biologics like ustekinumab—means profit margins will be squeezed unless firms differentiate through delivery mechanisms or value‑added services. Observers expect the next report to track whether these dynamics translate into sustained growth or a consolidation phase.